Biogen (MEX:BIIB) Land And Improvements

: MXN0 Mil (As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

Biogen's land and improvements for the quarter that ended in Mar. 2023 was MXN0 Mil.

Biogen's quarterly land and improvements increased from Sep. 2022 (MXN0 Mil) to Dec. 2022 (MXN3,946 Mil) but then declined from Dec. 2022 (MXN3,946 Mil) to Mar. 2023 (MXN0 Mil).

Biogen's annual land and improvements increased from Dec. 2020 (MXN2,383 Mil) to Dec. 2021 (MXN4,257 Mil) but then declined from Dec. 2021 (MXN4,257 Mil) to Dec. 2022 (MXN3,946 Mil).

Biogen Land And Improvements Historical Data

The historical data trend for Biogen's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Land And Improvements

2,837.26

2,227.37

2,383.06

4,256.66

3,945.99

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Land And Improvements																-	-	-	3,945.99	-

Biogen Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Biogen (MEX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

BIIB:USA IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.